Skip Navigation Skip to content

Business Development

Shilpa Medicare Limited is one of the largest specialty generic pharmaceutical companies in the world. We provide high-quality, affordable medicines trusted by healthcare professionals and patients in over 100 countries worldwide. Our global presence is supported by 06 manufacturing facilities.

We are in constant search of partners that match our values, work ethics and commitment to patients. We regard partnership and collaboration as an integral part of our business strategy. This important initiative is supported by a dedicated team for global business development, licensing and post-alliance management.

Our track-record of successful collaborations includes in/out licensing of products and technologies, joint ventures, as well as mergers & acquisitions. We offer a full range of both global and local integrated, organizational and commercial capabilities, combined with a track record of successful product launches. The financial strength of our company ensures appropriate investments in products.

In- Licensing

We constantly seek to strengthen our presence, with a range of generic and specialty products in Asia, US, Europe and other markets across the world.

We are currently interested in in-licensing products that are already marketed or are in late stage clinical development in our key therapy areas. We seek products that leverage our core strengths and complement our existing product portfolio in the following therapies:

  • Oncology
  • Neno Technology Products
  • Biotech

We seek to establish a long term, mutually rewarding relationship based on the business model of exclusive marketing rights for the aforementioned geographies, as well as for co-marketing or strategic alliances for co-development of products, including clinical trials for necessary regulatory approvals.

Out-Licensing

We possess the requisite expertise and experience to develop complex generic products which are bioequivalent, sustained release oral dosage forms and long acting injectable depot formulations.

Our out-licensing product range includes dosage forms for oral, injectable and Orally Disintegrating Strips.

Our Organic synthesis team develops highly complex bulk actives drugs. We offer over 45 API products manufactured at US FDA, EDQM, EDMF, PMDA, KFDA, approved sites.

Partner with Shilpa Medicare Limited

Please connect us at business

Mr. R K Somani
E-mail: somani@vbshilpa.com

Mr. Adam Levitt
E-mail: adam@vbshilpa.com

Mr. Janak Kastia
E-mail: janak.kastia@vbshilpa.com

Mr. R K Somani
E-mail: somani@vbshilpa.com

Mr. Dilip Chavan
E-mail: dilip.chavan@vbshilpa.com
API Asia, Latin America, Middle East, Africa and Euro Asia
Formulation Latin America, Euro Asia
Mr. Shankar Ramakrishan
E-mail: Shankar.rk@vbshilpa.com
Formulation Asia, Africa and Middle East